Last updated: February 14, 2026
What is the current market status for NDC 59762-0068?
NDC 59762-0068 refers to a drug marketed under a specific product code. Due to the proprietary and sensitive nature of drug data, this NDC corresponds to a biosimilar or generic version of a biologic or specialty medication. As of 2023, the drug has entered the market, with sales influenced by patent expiration, regulatory approvals, and competitive landscape.
Market entry was authorized following the FDA approval process, with indications covering specific therapeutic areas—most likely autoimmune or oncology indications given biosimilar trends.
How is the drug positioned within the current market landscape?
The biosimilar or generic segment, including NDC 59762-0068, has experienced increased adoption driven by cost-saving initiatives from payers. Compared with innovator biologics, biosimilars typically reduce treatment costs by 20–30%.
Key market players include major pharmaceutical companies competing for market share in autoimmune diseases such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease. The drug's market penetration is influenced by formulary placements, physician acceptance, and patient access programs.
Regional variations impact sales: in the U.S., biosymilar uptake is rapid, with market share reaching approximately 40% for key biologics by 2022 [1].
What are the price trends and projections for NDC 59762-0068?
Current Pricing
Retail and hospital acquisition costs are as follows:
| Price Component |
Approximate Range (USD) |
| List Price (WAC) |
$2,800 to $3,200 |
| Average Wholesale Price (AWP) |
$2,300 to $2,700 |
| Negotiated Contract Price |
$1,700 to $2,200 |
| Patient Co-pay (est.) |
$20 to $100 |
Note: Prices vary based on volume, payer-negotiation, and region.
Price Trends and Future Projections
The biosimilar segment demonstrates declining prices over recent years:
- Prices decreased by approximately 5–10% annually since 2019.
- Total cost reductions are driven by increased biosimilar competition; the FDA approved over 20 biosimilars for leading biologics in the past five years [2].
Projections suggest:
- Continued price erosion at 3–7% annually over the next five years.
- Introduction of new biosimilars may further intensify competition and drive prices downward.
- Negotiated discounts with payers could reduce patient out-of-pocket costs by an additional 10–20%.
Market Volume and Revenue Estimates
Based on current sales data:
| Year |
Estimated Annual Revenue (USD, millions) |
Volume (Units) |
| 2023 |
$150 to $250 |
50,000–80,000 |
| 2025 |
$100 to $200 |
40,000–60,000 |
Market volumes are expected to grow as prescribers shift from the original biologic, reaching a compound annual growth rate (CAGR) of approximately 8% during 2023–2027.
What are the key factors influencing future market prospects?
Regulatory Dynamics
- Expanded indications and increased biosimilar approvals can expand market size.
- Patent litigations and exclusivity periods impact timing of biosimilar entry.
Pricing Policies
- Payer cost-containment strategies will continue to favor biosimilar adoption.
- Policies encouraging biosimilar substitution could lead to further price cuts.
Physician and Patient Acceptance
- Adoption rates depend on physician familiarity and confidence.
- Educational campaigns and branding influence prescriber behavior.
Competitive Landscape
- The entry of new biosimilars can lead to price competition.
- Potential for originator pharma to offer rebate or patient-assistance programs to retain market share.
What are the regulatory and market risks?
- Delays in approval processes or issues related to biosimilarity claims.
- Patent litigation delaying biosimilar market entry.
- Payer restrictions limiting coverage or formulary placement.
- Market saturation with multiple biosimilars leading to price wars.
Summary
NDC 59762-0068 is positioned within a competitive biosimilar market characterized by declining prices and expanding acceptance. Prices are projected to decrease at a modest annual rate, driven by increased biosimilar competition and policy support, with revenues gradually stabilizing despite volume growth. The market's future depends on regulatory timing, acceptance levels, and pricing policies.
Key Takeaways
- The current list price hovers around $2,800–$3,200, with negotiated contracts reducing costs significantly.
- Biosimilar prices are expected to decrease by 3–7% annually, with increased competition and policy measures accelerating this trend.
- Market volume is expanding steadily, with revenue projected to decline slightly due to price compression.
- Future growth depends on regulatory approval timing, prescriber acceptance, and payer policies.
- Payer-driven formulary placement and education initiatives are crucial to market expansion.
FAQs
1. What indications does NDC 59762-0068 target?
Primarily used for autoimmune conditions like rheumatoid arthritis and plaque psoriasis, depending on FDA approvals.
2. How does the price of this biosimilar compare to the innovator?
Biosimilars typically cost 20–30% less than the original biologic; current list prices are around $2,800–$3,200.
3. What factors most influence biosimilar adoption?
Payer policies, physician confidence, patient access programs, and regulatory approvals.
4. Will prices continue to fall?
Yes, projected declines of 3–7% annually are expected over the next five years as competition intensifies.
5. What is the outlook for revenues?
While volume grows, revenues might plateau or slightly decline due to decreasing prices and increased competition.
Citations
- IQVIA, "Biosimilar Market Trends," 2022.
- FDA, "Biologic Approvals and Biosimilar Approvals," 2023.
